Q2 INTERIM REPORT April-June 2024

Mentice has received a 2.26 million USD order for simulation solutions from a top 20 global MedTech company

Mentice to present the company's Q1 Interim Report

Friday, April 26, 2024

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Ulrika Drotz.

The interim report for Q1-2024, covering the period from January to March 2024, is scheduled to be presented on May 3rd at 09:00 CEST. Carnegie equity analyst Klas Palin will moderate the live webcast. If you'd like to participate, please visit https://investor.mentice.com/ for more information.

The presentation will be conducted in English.

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB